Page last updated: 2024-11-05

gamma-valerolactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Gamma-valerolactone (GVL) is a cyclic organic compound with a five-membered ring. It is a colorless liquid with a sweet odor. GVL is a versatile platform chemical that can be produced from renewable resources like biomass. It has several potential applications in the chemical industry, including as a fuel additive, a solvent, and a monomer for the production of polymers. GVL can be synthesized through various routes, including hydrogenation of levulinic acid, dehydration of 1,4-butanediol, and the catalytic conversion of biomass. GVL is considered a sustainable and renewable alternative to petroleum-based chemicals. Research on GVL focuses on improving its synthesis methods, exploring new applications, and assessing its environmental impact.'

gamma-valerolactone: metabolite of n-hexane; RN given refers to cpd with methyl moiety in position 5 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

gamma-valerolactone : A butan-4-olide that is dihydrofuran-2(3H)-one substituted by a methyl group at position 5. It has been found in the urine samples of humans exposed to n-hexane. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7921
CHEMBL ID195593
CHEBI ID48569
SCHEMBL ID37255
MeSH IDM0113567

Synonyms (99)

Synonym
5-methyldihydro-2(3h)-furanone
.gamma.-valerolactone
2(3h)-furanone, dihydro-5-methyl-, (.+/-.)-
4-hydroxyvaleric acid lactone
4-valerolactone
pentanoic acid, .gamma.-lactone
.gamma.-pentalactone
nsc33700
108-29-2
nsc-33700
.gamma.-methyl-.gamma.-butyrolactone
4-methyl-.gamma.-butyrolactone
2(3h)-furanone, dihydro-5-methyl-
4-hydroxypentanoic acid lactone
4-pentanolide
2(3h)-furanone, dihydr-5-methyl-
gamma-valerolakton [czech]
pentanoic acid, 4-hydroxy-, gamma-lactone
einecs 203-569-5
ai3-04327
gamma-methyl-gamma-butyrolactone
valeric acid, 4-hydroxy-, gamma-lactone
5-methyltetrahydro-2-furanone
nsc 33700
pentanolide-1,4
ccris 3597
brn 0080420
fema no. 3103
gamma-valeryllactone
gamma-valerolactone
gamma-valerolactone, >=99%, fcc, fg
gamma-valerolactone, reagentplus(r), 99%
CHEBI:48569 ,
4-methyl-4-hydroxybutanoic acid lactone
gamma-pentanolactone
gamma-pentalactone
4-methyl-gamma-butyrolactone
dihydro-5-methyl-2(3h)-furanone
5-methyldihydrofuran-2(3h)-one
5-methyloxolan-2-one
bdbm50168010
dihydro-5-methyl-2(3h)-furanone,
CHEMBL195593 ,
V0007
o7056xk37x ,
gamma-valerolakton
unii-o7056xk37x
5-17-09-00024 (beilstein handbook reference)
EN300-61318
dihydro-5-methylfuran-2(3h)-one
LMFA07040008
dtxcid8027618
tox21_302624
dtxsid0047618 ,
cas-108-29-2
NCGC00256671-01
AKOS005206963
BBL011475
STL146587
FT-0626628
FT-0605160
valeric acid, 4-hydroxy-, .gamma.-lactone
(+/-)-.gamma.-methylbutyrolactone
.gamma.-valerolactone [fhfi]
(rs)-.gamma.-pentalactone
4-hydroxypentanoic acid .gamma.-lactone
pentanoic acid, 4-hydroxy-, .gamma.-lactone
gamma-valerolactone [fcc]
5-methyl-dihydro-furan-2-one
SCHEMBL37255
(.+/-.)-4-methylbutyrolactone
(.+/-.)-.gamma.-valerolactone
5-methyldihydro-2(3h)-furanone #
dihydro-5-methyl-2-furanone
.gamma.-pentanolactone
.gamma.-valerolakton
5-methyltetrahydrofuran-2-one
mfcd00005400
J-002085
F0001-0163
y-valerolactone
gamma-valerolactone, analytical standard
gamma-valerolactone, vetec(tm) reagent grade, 98%
gamma-valerolactone, natural, 95%, fg
4-methyl-g-butyrolactone
SY011304
DS-4944
gamma-valerolactone,delta-valerolactone
Q845530
(3-amino-pyridin-2-yl)-aceticacid
BP-31066
P20539
4,5-dihydro-5-methyl-2(3h)-furanone~4-hydroxypentanoic acid lactone~gamma-pentanolactone
A895293
gamma -valerolactone
CS-W016654
219630-19-0
HY-W015938
Z963595138

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The aim of this study was to investigate green tea flavan-3-ol catabolism and plasma pharmacokinetic and urinary excretion by high-performance liquid chromatography with tandem mass spectrometry to evaluate their absolute bioavailability by taking into account all known and some unknown catabolites deriving from their interaction with the gastrointestinal tract and its host microflora."( Bioavailability and catabolism of green tea flavan-3-ols in humans.
Brighenti, F; Calani, L; Cordero, C; Del Rio, D; Pellegrini, N; Salvatore, S,
)
0.13
" The calculated bioavailability was equal to 39% and it is interesting to notice the great variability in urinary excretion of colonic metabolites among participants, probably related to differences in their own colonic microflora."( Bioavailability and catabolism of green tea flavan-3-ols in humans.
Brighenti, F; Calani, L; Cordero, C; Del Rio, D; Pellegrini, N; Salvatore, S,
)
0.13
" The formation, bioavailability and pharmacokinetics of PVLs and PVAs from different types of flavan-3-ols are discussed, taking into account in vitro and animal studies, as well as inter-individual differences and the existence of putative flavan-3-ol metabotypes."( Phenyl-γ-valerolactones and phenylvaleric acids, the main colonic metabolites of flavan-3-ols: synthesis, analysis, bioavailability, and bioactivity.
Angelino, D; Bresciani, L; Brighenti, F; Brindani, N; Calani, L; Clifford, MN; Crozier, A; Curti, C; Del Rio, D; Gill, CIR; Llorach, R; Ludwig, IA; Mena, P; Pereira-Caro, G, 2019
)
0.51
" However, phenolics like flavan-3-ols (F3O) are poorly absorbed along the gastrointestinal tract and structurally rearranged by gut microbiota, yielding smaller and more polar metabolites like phenyl-γ-valerolactones, phenylvaleric acids and their conjugates."( 5-(Hydroxyphenyl)-γ-Valerolactone-Sulfate, a Key Microbial Metabolite of Flavan-3-ols, Is Able to Reach the Brain: Evidence from Different in
Angelino, D; Bladé, C; Brighenti, F; Brindani, N; Brito, MA; Carregosa, D; Curti, C; Davis, CD; Del Bas, JM; Del Rio, D; Domenech-Coca, C; Figueira, I; Jang, S; Kim, KS; Lakshman, S; Mena, P; Molokin, A; Santos, CND; Savi, M; Solano-Aguilar, GI; Stilli, D; Urban, JF, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" This investigation focused on effects of various reaction conditions including solvent, acid catalyst, reaction temperature, residence time, water concentration, xylose loading and catalyst dosage on the dehydration of xylose to furfural."( Conversion of corn stalk into furfural using a novel heterogeneous strong acid catalyst in γ-valerolactone.
Chang, HM; Du, Z; Jameel, H; Li, W; Ma, L; Wu, H; Xu, Z, 2015
)
0.42
" The influence of the reaction time, temperature and dosage of catalyst on xylose dehydration were also investigated."( Catalytic conversion of xylose and corn stalk into furfural over carbon solid acid catalyst in γ-valerolactone.
Chang, HM; Jameel, H; Li, W; Liu, Q; Ma, L; Ma, Q; Xu, Z; Zhang, T, 2016
)
0.43
" Furthermore, the effect of oral single dosage of EGC-M5 on glucose tolerance test with ICR mice was examined and significant suppression of hyperglycemia was observed."( Effects of Microbial Metabolites of (-)-Epigallocatechin Gallate on Glucose Uptake in L6 Skeletal Muscle Cell and Glucose Tolerance in ICR Mice.
Ashida, H; Hara-Terawaki, A; Ikeda, M; Nagano, T; Seto, R; Takagaki, A; Yamashita, Y; Yoshioka, Y, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
flavouring agentA food additive that is used to added improve the taste or odour of a food.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
butan-4-olideAny gamma-lactone having the lactone moiety derived from 4-hydroxybutanoic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki4.69000.00001.372610.0000AID639299
Carbonic anhydrase 2Homo sapiens (human)Ki100.00000.00000.72369.9200AID639300
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)15,000.00000.00011.774010.0000AID241334
Carbonic anhydrase 9Homo sapiens (human)Ki0.92000.00010.78749.9000AID639301
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID639299Inhibition of human CA1 pre-incubated for 15 mins to 24 hrs measured after 6 hrs by phenol red-based stopped-flow CO2 hydrase assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
5- and 6-membered (thio)lactones are prodrug type carbonic anhydrase inhibitors.
AID639300Inhibition of human CA2 pre-incubated for 15 mins to 24 hrs measured after 6 hrs by phenol red-based stopped-flow CO2 hydrase assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
5- and 6-membered (thio)lactones are prodrug type carbonic anhydrase inhibitors.
AID241334Inhibitory concentration against recombinant human cytochrome P450 1A22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
AID639301Inhibition of human CA9 pre-incubated for 15 mins to 24 hrs measured after 6 hrs by phenol red-based stopped-flow CO2 hydrase assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
5- and 6-membered (thio)lactones are prodrug type carbonic anhydrase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (122)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (4.10)18.7374
1990's1 (0.82)18.2507
2000's8 (6.56)29.6817
2010's82 (67.21)24.3611
2020's26 (21.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (3.25%)5.53%
Reviews6 (4.88%)6.00%
Case Studies1 (0.81%)4.05%
Observational1 (0.81%)0.25%
Other111 (90.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]